ATE343786T1 - Auswertung von agenzien zur behandlung von schizophrenie - Google Patents

Auswertung von agenzien zur behandlung von schizophrenie

Info

Publication number
ATE343786T1
ATE343786T1 AT02078387T AT02078387T ATE343786T1 AT E343786 T1 ATE343786 T1 AT E343786T1 AT 02078387 T AT02078387 T AT 02078387T AT 02078387 T AT02078387 T AT 02078387T AT E343786 T1 ATE343786 T1 AT E343786T1
Authority
AT
Austria
Prior art keywords
schizophrenia
treatment
evaluation
agents
agent
Prior art date
Application number
AT02078387T
Other languages
English (en)
Inventor
Peter Ronald Maycox
Charles Alan Reavill
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE343786T1 publication Critical patent/ATE343786T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
AT02078387T 2001-08-22 2002-08-16 Auswertung von agenzien zur behandlung von schizophrenie ATE343786T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0120349.6A GB0120349D0 (en) 2001-08-22 2001-08-22 Model

Publications (1)

Publication Number Publication Date
ATE343786T1 true ATE343786T1 (de) 2006-11-15

Family

ID=9920767

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02078387T ATE343786T1 (de) 2001-08-22 2002-08-16 Auswertung von agenzien zur behandlung von schizophrenie

Country Status (5)

Country Link
US (1) US7038105B2 (de)
EP (1) EP1286163B1 (de)
AT (1) ATE343786T1 (de)
DE (1) DE60215594T2 (de)
GB (1) GB0120349D0 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626832B1 (de) 2014-11-25 2024-06-12 The Brigham and Women's Hospital, Inc. Verfahren zur identifizierung einer person mit einer prädisposition für eine kardiometabolische krankheit oder eine davon betroffene person
US10683552B2 (en) 2014-11-25 2020-06-16 Presidents And Fellows Of Harvard College Clonal haematopoiesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2199455A1 (en) * 1997-03-07 1998-09-07 Jerold J. M. Chun Cloned lysophosphatidic acid receptors
US20020061558A1 (en) * 2000-06-12 2002-05-23 Nabil Elshourbagy Mouse G protein coupled receptor EDG7
US20020090691A1 (en) * 2000-07-13 2002-07-11 Elshourbagy Nabil A. Mouse seven trans-membrane receptor EDG4

Also Published As

Publication number Publication date
DE60215594T2 (de) 2007-08-23
GB0120349D0 (en) 2001-10-17
EP1286163A3 (de) 2003-04-16
DE60215594D1 (de) 2006-12-07
US7038105B2 (en) 2006-05-02
US20030056236A1 (en) 2003-03-20
EP1286163B1 (de) 2006-10-25
EP1286163A2 (de) 2003-02-26

Similar Documents

Publication Publication Date Title
DE60227658D1 (de) Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren
ATE441663T1 (de) Verfahren und zusammensetzungen für amyloidosis- verbundene krankheiten
EA200201247A1 (ru) Соединения для лечения болезни альцгеймера
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
ATE308997T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
DK1790354T3 (da) Anvendelse af plasminogen til sårheling
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
ATE349446T1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
DE60237635D1 (de) Verwendung von pramipexol zur behandlung von amyotrophischer lateralsklerose
ATE444086T1 (de) Therapeutische zusammensetzungen und verfahren zur behandlung von periodontitis mit entzündunshemmenden mitteln
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
ATE338575T1 (de) Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE343786T1 (de) Auswertung von agenzien zur behandlung von schizophrenie
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
ATE314861T1 (de) Verwendung von antikörper gegen mag zur behandlung ischämischer schlaganfälle
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
DE60120961D1 (de) Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties